Company Overview of Virobay Inc.
Virobay, Inc., a clinical-stage pharmaceutical company, develops and commercializes drugs for the treatment of neuropathic pain, autoimmune diseases, and fibrosis. The company is developing VBY-036, a cathepsin S inhibitor, which has completed Phase I clinical trials for the treatment of neuropathic pain and crohn’s disease; and VBY-891, a cathepsin S inhibitor that has completed Phase I clinical trials for the treatment of psoriasis. It is also developing VBY-376, a cathepsin B inhibitor, which has completed a Phase I clinical trial to treat liver fibrosis in patients with nonalcoholic steatohepatitis; and VBY-825, an inhibitor of multiple cathepsins that is in preclinical studies for treat...
1360 Willow Road
Menlo Park, CA 94025
Founded in 2006
Key Executives for Virobay Inc.
Co-Founder, Chairman, Chief Executive Officer, President and Secretary
Co-Founder, Director, Chairperson of Nominating & Corporate Governance Committee and Member of Audit Committee
Chief Financial & Accounting Officer and Senior Vice President
Senior Vice President of Project Management and Operations
Compensation as of Fiscal Year 2014.
Virobay Inc. Key Developments
Virobay Appoints James Welch as Chief Financial Officer
Jun 25 14
Virobay Inc. announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014. Prior to joining Virobay, Mr. Welch was Chief Financial Officer at AcelRx Pharmaceuticals.
Virobay Inc. Initiates Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
May 23 13
Virobay Inc. announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor. The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults. The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay. Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year. VBY-891 is being developed in partnership with LEO Pharma for the therapy of dermatological diseases.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries